• James E Sharman, Eoin O'Brien, Bruce Alpert, Aletta E Schutte, Christian Delles, Michael Hecht Olsen, Roland Asmar, Neil Atkins, Eduardo Barbosa, David Calhoun, CampbellNorm R CNRCDepartamento de Medicina, Fisiología y Farmacología y Ciencias de la Salud Comunitaria, O'Brien Institute for Public Health y Libin Cardiovascular Institute of Alberta Universidad de Calgary CalgaryAlberta Canadá Departamento de Medicin, John Chalmers, Ivor Benjamin, Garry Jennings, Stéphane Laurent, Pierre Boutouyrie, Patricio Lopez-Jaramillo, Richard J McManus, Anastasia S Mihailidou, Pedro Ordunez, Raj Padwal, Paolo Palatini, Gianfranco Parati, Neil Poulter, Michael K Rakotz, Clive Rosendorff, Francesca Saladini, Angelo Scuteri, Weimar Sebba Barroso, Myeong-Chan Cho, Ki-Chul Sung, Raymond R Townsend, Ji-Guang Wang, Tine Willum Hansen, Gregory Wozniak, George Stergiou, and en nombre del Grupo de la Comisión Lancet de Hipertensión
.
• Menzies Institute for Medical Research Universidad de Tasmania HobartTasmania Australia Menzies Institute for Medical Research, Universidad de Tasmania, Hobart, Tasmania, Australia.
• Rev. Panam. Salud Publica. 2020 Jan 1; 44: e21.

AbstractThe Lancet Commission on Hypertension identified that a key action to address the worldwide burden of high blood pressure (BP) was to improve the quality of BP measurements by using BP devices that have been validated for accuracy. Currently, there are over 3 000 commercially available BP devices, but many do not have published data on accuracy testing according to established scientific standards. This problem is enabled through weak or absent regulations that allow clearance of devices for commercial use without formal validation. In addition, new BP technologies have emerged (e.g. cuffless sensors) for which there is no scientific consensus regarding BP measurement accuracy standards. Altogether, these issues contribute to the widespread availability of clinic and home BP devices with limited or uncertain accuracy, leading to inappropriate hypertension diagnosis, management and drug treatment on a global scale. The most significant problems relating to the accuracy of BP devices can be resolved by the regulatory requirement for mandatory independent validation of BP devices according to the universally-accepted International Organization for Standardization Standard. This is a primary recommendation for which there is an urgent international need. Other key recommendations are development of validation standards specifically for new BP technologies and online lists of accurate devices that are accessible to consumers and health professionals. Recommendations are aligned with WHO policies on medical devices and universal healthcare. Adherence to recommendations would increase the global availability of accurate BP devices and result in better diagnosis and treatment of hypertension, thus decreasing the worldwide burden from high BP.

4 keywords...

hide…